Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dantron→

Dantron Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
117-10-2
Molecular formula
C14H8O4
Molecular weight
240.21 g/mol
Drug class
Anthraquinone stimulant laxative (historical agent)
Mechanism of action
Stimulates colonic motility and reduces net water and electrolyte absorption in the large intestine, increasing bowel evacuation. The exact mechanism is not fully characterised; use was restricted because of carcinogenicity concerns.
Indications / reported uses
  • Historical short-term treatment of constipation. Dantron-containing laxatives have been withdrawn or restricted in many jurisdictions due to genotoxicity and carcinogenicity concerns and should not be presented as routine current therapy.

Sources: NLM MeSH — Dantron · PubMed — Dantron carcinogenicity and laxative use · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Anthraquinone stimulant laxative (historical agent)

Mechanism of action

Stimulates colonic motility and reduces net water and electrolyte absorption in the large intestine, increasing bowel evacuation. The exact mechanism is not fully characterised; use was restricted because of carcinogenicity concerns.

General use cases

  • Historical short-term treatment of constipation. Dantron-containing laxatives have been withdrawn or restricted in many jurisdictions due to genotoxicity and carcinogenicity concerns and should not be presented as routine current therapy.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Dantron Environmental Risk Assessment (ERA) (the Dantron ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.